Research Analysts Issue Forecasts for Arvinas Q1 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of Arvinas in a note issued to investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.76) per share for the quarter, up from their previous forecast of ($0.93). Wedbush currently has a “Neutral” rating and a $12.00 target price on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the firm posted ($2.53) EPS.

ARVN has been the topic of several other research reports. Citigroup cut their price objective on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $81.00 price objective on shares of Arvinas in a report on Tuesday, March 11th. BTIG Research began coverage on Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price objective on the stock. Stifel Nicolaus cut their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Finally, Oppenheimer downgraded Arvinas from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 11th. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Arvinas presently has an average rating of “Moderate Buy” and a consensus price target of $37.47.

Arvinas Stock Down 1.4 %

Shares of Arvinas stock opened at $8.43 on Monday. Arvinas has a 52 week low of $7.91 and a 52 week high of $45.77. The business’s fifty day simple moving average is $17.32 and its 200-day simple moving average is $21.84. The firm has a market cap of $579.75 million, a PE ratio of -3.04 and a beta of 1.95.

Insiders Place Their Bets

In other news, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,572 shares of company stock worth $695,030 in the last quarter. 5.23% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new position in shares of Arvinas in the 4th quarter valued at about $28,000. KBC Group NV boosted its position in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Quantbot Technologies LP boosted its position in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas in the 4th quarter valued at about $171,000. Finally, Tema Etfs LLC acquired a new stake in shares of Arvinas in the 4th quarter valued at about $227,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.